Display options
Cite
Paolicelli D, Direnzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics. 2009;3:369-76
Paolicelli, D., Direnzo, V., & Trojano, M. (2009). Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics : targets & therapy, 3369-76.
Paolicelli, Damiano, et al. "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis." Biologics : targets & therapy vol. 3 (2009): 369-76.
Paolicelli D, Direnzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics. 2009;3:369-76. Epub 2009 Jul 13. PMID: 19707422; PMCID: PMC2726074.
Copy Download .nbib Format: NLM
Share it on

Biologics. 2009;3:369-76. Epub 2009 Jul 13.

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.

Biologics : targets & therapy

Damiano Paolicelli, Vita Direnzo, Maria Trojano

Affiliations

  1. Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy.

PMID: 19707422 PMCID: PMC2726074

Abstract

Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNbeta-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFNbeta-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFNbeta-1b was administered to still-active secondary progressive MS. IFNbeta-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFNbeta-1b still remains a first-line therapy with a fundamental role in all stages of the disease.

Keywords: clinically isolated syndromes; efficacy; interferon beta-1b; neutralizing antibodies; relapsing-remitting multiple sclerosis; safety

References

  1. J Exp Med. 1995 Nov 1;182(5):1517-25 - PubMed
  2. Clin Neurol Neurosurg. 2004 Jun;106(3):255-8 - PubMed
  3. Ann Neurol. 1997 May;41(5):669-74 - PubMed
  4. Ann Neurol. 1996 Dec;40(6):853-63 - PubMed
  5. J Neuroimmunol. 1996 Jul;67(2):111-8 - PubMed
  6. J Interferon Res. 1993 Oct;13(5):333-40 - PubMed
  7. J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50 - PubMed
  8. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5662-6 - PubMed
  9. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S19-24 - PubMed
  10. Neurology. 2003 Jan 14;60(1):37-43 - PubMed
  11. Ann Neurol. 1983 Mar;13(3):227-31 - PubMed
  12. Ann Neurol. 1990 Feb;27(2):207-10 - PubMed
  13. Neurology. 2008 Mar 25;70(13 Pt 2):1119-27 - PubMed
  14. Neurology. 1999 Apr 12;52(6):1277-9 - PubMed
  15. Drug Saf. 2000 Feb;22(2):149-59 - PubMed
  16. Neurology. 1993 Apr;43(4):655-61 - PubMed
  17. Pharm Res. 1993 Apr;10(4):567-72 - PubMed
  18. Clin Pharmacokinet. 1990 Nov;19(5):390-9 - PubMed
  19. Neurology. 2005 Jul 12;65(1):40-7 - PubMed
  20. Arch Neurol. 2007 Sep;64(9):1292-8 - PubMed
  21. Neurology. 2006 Apr 11;66(7):1056-60 - PubMed
  22. Neurology. 2001 Dec 11;57(11):1969-75 - PubMed
  23. Ann Neurol. 2005 Dec;58(6):840-6 - PubMed
  24. Lancet. 2001 May 19;357(9268):1576-82 - PubMed
  25. Neurology. 2006 Oct 10;67(7):1242-9 - PubMed
  26. N Engl J Med. 1998 Jan 29;338(5):278-85 - PubMed
  27. Neurology. 1999 Nov 10;53(8):1622-7 - PubMed
  28. Neurology. 1998 May;50(5):1294-300 - PubMed
  29. Arch Neurol. 2001 Jan;58(1):65-70 - PubMed
  30. Ann Neurol. 2004 Apr;55(4):458-68 - PubMed
  31. Lancet. 1998 Nov 7;352(9139):1491-7 - PubMed
  32. J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51 - PubMed
  33. J Int Med Res. 2007 Mar-Apr;35(2):173-87 - PubMed
  34. Neurology. 1996 Oct;47(4):889-94 - PubMed
  35. J Neurol. 2008 Apr;255(4):480-7 - PubMed
  36. Lancet. 2007 Aug 4;370(9585):389-97 - PubMed
  37. Neurology. 1995 Jul;45(7):1277-85 - PubMed
  38. Neurology. 1993 Apr;43(4):662-7 - PubMed
  39. Brain. 2002 Oct;125(Pt 10):2202-12 - PubMed
  40. Lancet. 2002 Apr 27;359(9316):1453-60 - PubMed
  41. J Neuroimmunol. 1993 Jul;46(1-2):145-53 - PubMed
  42. Ann Neurol. 2007 Apr;61(4):300-6 - PubMed
  43. Lancet. 2003 Oct 11;362(9391):1184-91 - PubMed
  44. Mult Scler. 2004 Apr;10(2):126-38 - PubMed
  45. N Engl J Med. 2000 Sep 28;343(13):898-904 - PubMed
  46. Neurology. 2004 Mar 9;62(5):719-25 - PubMed
  47. Ann Neurol. 1996 Dec;40(6):846-52 - PubMed

Publication Types